Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

CRBU

NASDAQ

Caribou Biosciences (CRBU)

0.2954 USD −6.04% vs prior close Nov 20, 2026
Caribou Biosciences, Inc. price graph
32 sessions
1.5 0.0 14 Sep 20 Nov

The line runs 1.30 USD on 14 September through 0.2954 USD on 20 November, on a scale from 0.0 to 1.5. Days the market did not trade hold the previous close, flat.

Market cap
31.9M USD
Revenue, year to Dec 2025
11.2M USD
EPS, diluted, year to Dec 2025
−1.59 USD
Avg volume
129.4K

as of Nov 20, 2026

Have Caribou Biosciences (CRBU) insiders bought or sold shares recently?

CRBU's newest Form 4 filing is dated 25 February 2026: none in the last 90 days.

Form 4

Have Caribou Biosciences (CRBU) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
25 Feb 2026Kelly Timothy PChief Technology OfficerSell6,22812K USD
24 Feb 2026Albertson Tina M.Chief Medical OfficerSell1,0662K USD
24 Feb 2026MCCLUNG BARBARA GChief Legal OfficerSell6,93814K USD
24 Feb 2026Kelly Timothy PChief Technology OfficerSell3,1476K USD
24 Feb 2026Khan Ruhi AhmadChief Business OfficerSell6,93814K USD
Sold5 open-market sales24,317$47K
6 other filings: grants, exercises, tax withholding and transfers, not trades
Have Caribou Biosciences (CRBU) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
20 Feb 2026Albertson Tina M.Chief Medical OfficerAward55,000
20 Feb 2026MCCLUNG BARBARA GChief Legal OfficerAward45,000
20 Feb 2026Kelly Timothy PChief Technology OfficerAward45,000
20 Feb 2026Khan Ruhi AhmadChief Business OfficerAward45,000
20 Feb 2026Haurwitz Rachel E.President and CEOAward151,700
20 Feb 2026Ryali SriramChief Financial OfficerAward55,000

Which funds hold Caribou Biosciences (CRBU)?

7 of the 45 institutional funds we track reported a Caribou Biosciences position for the quarter ended 30 Sep 2026 — a combined 8.3M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Caribou Biosciences (CRBU)?
FundPositionSharesValueShares q/q
Renaissance TechnologiesHeld (±25%)2,556,0083.2M USD−7.8%
AQR Capital ManagementNew position1,632,6732.1M USD
Two Sigma InvestmentsTrimmed674,627857K USD−35.5%
Maverick CapitalHeld (±25%)652,542829K USD
Marshall WaceAdded575,216731K USD+53.1%
Man GroupAdded327,502416K USD+36.4%
Citadel AdvisorsAdded107,367136K USD+165.7%
Millennium ManagementExited
Point72 Asset ManagementExited

What has been filed or recorded for Caribou Biosciences (CRBU)?

The filings we hold for Caribou Biosciences, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 23 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Caribou Biosciences (CRBU)?
And
23 Oct 2026Fails to deliverShares failed to deliver99,809 shares56K USD notional · 0.092% of shares out
19 Oct 2026Fails to deliverShares failed to deliver21 shares10 USD notional · <0.001% of shares out
16 Oct 2026Fails to deliverShares failed to deliver149 shares69 USD notional · <0.001% of shares out
15 Oct 2026Fails to deliverShares failed to deliver77,671 shares36K USD notional · 0.072% of shares out
08 Oct 2026Fails to deliverShares failed to deliver74,206 shares46K USD notional · 0.069% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.25 USD
30 Sep 2026FinancialsTotal assets123.0M USDat period end
30 Sep 2026FinancialsTotal equity76.6M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.24 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.26 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.59 USD
31 Dec 2025FinancialsRevenue11.2M USDfiscal year
31 Dec 2025FinancialsNet income−148.1M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.59 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.30 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.58 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.43 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.65 USD

What do people ask about Caribou Biosciences (CRBU)?

From live data
What did Caribou Biosciences shares close at?0.2954

Caribou Biosciences closed at 0.2954 USD on 20 Nov 2026, down 6.04% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Caribou Biosciences’ market cap?31.9M

Caribou Biosciences is worth 31.9M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Caribou Biosciences’ revenue?11.2M

Caribou Biosciences reported revenue of 11.2M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Caribou Biosciences insiders bought or sold shares recently?

No Caribou Biosciences insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 25 Feb 2026 (SEC Form 4). See Insiders

Which funds own Caribou Biosciences?7 of 45

7 of the 45 funds we track reported a Caribou Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, AQR Capital Management and Two Sigma Investments. See Funds

When did Caribou Biosciences last report earnings?−0.25

Caribou Biosciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.25 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words